Table 2.
Summary of patient characteristics and demographics and change in BMD following discontinuation of etidronate or alendronate.
Didronel PMO (n = 19) | Fosamax (n = 16) | |
Age at Discontinuation (mean [SD]) | 64.3 [14.41] | 69.4 [9.23] |
Years on Treatment (mean [SD]) | 6.8 [2.21] | 5.6 [1.03] * |
Age at Menarche (mean [SD]) | 13.0 [1.664] | 12.8 [2.49] |
Number of years since menopause (mean [SD]) | 24.7 [9.18] | 27.36 [9.04] |
Milk Intake ≥ 1/2 pint/day (%) | 15.8 | 6.25 |
Walking < 30 minutes/day | 36.48 | 25 |
(%) > 1 hour/day | 5.26 | 12.5 |
Previous fragility fracture(s) (%) | 26.32 | 37.5 |
BMI (Kg/m2) (mean [SD]) | 25.47 [6.27] | 26.48 [4.67] |
Current and Ex-Smokers (%) | 36.84 | 18.75 |
Alcohol Intake ≤ 14 units/week (%) | 52.63 | 37.5 |
Positive Family History of Osteoporosis (%) | 42.12 | 25 |
Lumbar Spine BMD at discontinuation (g/cm2) (mean [SD]) | 0.856 [0.118] | 0.761 [0.106] |
Lumbar Spine BMD after discontinuation (g/cm2) (mean [SD]) | 0.855 [0.107] | 0.769 [0.106] |
Total Hip BMD at discontinuation (g/cm2) (mean [SD]) | 0.794 [0.133] | 0.739 [0.105] |
Total Hip BMD after discontinuation (g/cm2) (mean [SD]) | 0.792 [0.129] | 0.736 [0.099] |
* p = 0.029